Oral Drug Wins FDA Approval for Chronic Hives

Novartis Nabs FDA Approval for First-of-Its-Kind Drug for Chronic Hives

Novartis drug Rhapsido is now approved as a second-line treatment for chronic spontaneous urticaria, a rare inflammatory skin disease. Additional clinical trials are ongoing to support potential expansion of the twice-daily pill to other immunological disorders. The post Novartis Nabs FDA Approval for First-of-Its-Kind Drug for Chronic Hives appeared first on MedCity News.

Oral Drug Wins FDA Approval for Chronic Hives

(MedPage Today) -- The FDA approved oral remibrutinib (Rhapsido) as a second-line treatment for chronic spontaneous urticaria (CSU), or chronic hives, Novartis announced on Tuesday. Indicated for adults with stubborn symptoms despite the use of...

FDA clears Novartis' oral drug for chronic hives

Novartis has claimed a first-in-class approval in the US for its oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria.

Novartis Gains US Approval for New Approach to Chronic Hives

Novartis AG won US approval for a new treatment for a hives-like skin condition, bolstering the Swiss drugmaker’s push into disorders of the immune system.

Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)

Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment 1

Novartis wins FDA approval of BTK inhibitor remibrutinib for urticaria

FDA approves Novartis' Rhapsido, the first oral BTK inhibitor for chronic spontaneous urticaria. Read more here.